Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.
Eleni SflakidouGeorge LeonidisEirini ForoglouChristos SiokatasVasiliki SarliPublished in: Molecules (Basel, Switzerland) (2022)
Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times. Although natural compounds and their derivatives have demonstrated strong antitumor activity in many types of cancer, their poor pharmacokinetic properties, low cell selectivity, limited bioavailability and restricted efficacy against drug-resistant cancer cells hinder their wide clinical application. Conjugation of natural products with other bioactive molecules has given rise to a new field in drug discovery resulting to the development of novel, bifunctional and more potent drugs for cancer therapy to overcome the current drawbacks. This review discusses multiple categories of such bifunctional conjugates and highlights recent trends and advances in the development of natural product hybrids. Among them, ADCs, PDCs, ApDCs, PROTACs and AUTOTACs represent emerging therapeutic agents against cancer.
Keyphrases
- papillary thyroid
- drug resistant
- cell proliferation
- squamous cell
- cancer therapy
- multidrug resistant
- drug discovery
- lymph node metastasis
- squamous cell carcinoma
- oxidative stress
- cell death
- cell cycle
- cell therapy
- bone marrow
- childhood cancer
- signaling pathway
- mesenchymal stem cells
- combination therapy
- young adults
- cell cycle arrest
- replacement therapy
- pi k akt